Bladder Cancer Trial Affirms Benefit of Immunotherapy after Surgery - Cancer Currents Blog

The latest from the NCI Cancer Currents blog

Having trouble viewing this email? View it as a Web page.

Immunotherapy after Surgery Shows Long-Term Benefits for High-Risk Bladder Cancer 03/21/2023 Updated results from a large clinical trial confirm that, for some people with bladder cancer, receiving immunotherapy after surgery is an effective treatment. In 2021, initial results from the same trial led to FDA approval of nivolumab (Opdivo) for this use. UPDATE: FDA approves targeted therapy combination for some kids with the brain cancer glioma On March 16, 2023, FDA approved the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) for the treatment of some children with low-grade glioma. The approval was based on the results of a clinical trial, discussed in this June 2022 Cancer Currents story. You are subscribed to the latest posts from Cancer Currents: An NCI Cancer Research Blog from the National Cancer Institute. Update your subscriptions.

Stay Connected with the National Cancer Institute
Chat with us: LiveHelp  Call us: 1-800-4-CANCER (1-800-422-6237) SUBSCRIBER SERVICES: Manage Subscriptions  |  Help

 

This email was sent to myhcistech.healthnews360@blogger.com using GovDelivery Communications Cloud on behalf of: National Cancer Institute · BG 9609 MSC 9760 · 9609 Medical Center Drive · Bethesda, MD 20892